This database contains 22 studies, archived under the term: "pharmacokinetics"
Click here to filter this large number of results.
Concentration of donepezil to the cognitive response in Alzheimer disease
Yang, Yuan-Han,
Chen, Chun-Hung,
Chou, Mei-Chuan,
Li, Chien-Hsun,
Liu, Ching-Kuan,
Chen, Su-Hwei
Background: Donepezil has been approved, and higher dosages are recommended for the treatment of Alzheimer disease (AD). However, a few studies have reported different cognitive responses in patients with AD treated with donepezil without measuring the concentration.; Methods: We evaluated the relationships between the therapeutic responses and plasma concentrations of donepezil in various cognitive domains […]
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study
Sink, Kaycee M.,
Leng, Xiaoyan,
Williamson, Jeff,
Kritchevsky, Stephen B.,
Yaffe, Kristine,
Kuller, Lewis,
Yasar, Sevil,
Atkinson, Hal,
Robbins, Mike,
Psaty, Bruce,
Goff, David C.
Background: Hypertension (HTN) is a risk factor for dementia, and animal studies suggest that centrally active angiotensin-converting enzyme (ACE) inhibitors (those that cross the blood-brain barrier) may protect against dementia beyond HTN control.; Methods: Participants in the Cardiovascular Health Study Cognition Substudy with treated HTN and no diagnosis of congestive heart failure (n = 1054; […]
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET
Shokouhi, S.,
Claassen, D.,
Kang, H.,
Ding, Z.,
Rogers, B.,
Mishra, A.,
Riddle, W. R.
Unlabelled: Evaluating the symptomatic progression of mild cognitive impairment (MCI) caused by Alzheimer disease (AD) is practically accomplished by tracking performance on cognitive tasks, such as the Alzheimer Disease Assessment Scale’s cognitive subscale (ADAS_cog), the Mini-Mental Status Examination (MMSE), and the Functional Activities Questionnaire (FAQ). The longitudinal relationships between cognitive decline and metabolic function as […]
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation
Nathan, Pradeep J.,
Boardley, Rebecca,
Scott, Nicola,
Berges, Alienor,
Maruff, Paul,
Sivananthan, Tharani,
Upton, Neil,
Lowy, Martin T.,
Nestor, Peter J.,
Lai, Robert
Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H₃ receptor antagonist developed for the treatment of cognitive dysfunction in neurodegenerative disorders. In this study […]
Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy
Miyoshi, F.,
Ogawa, T.,
Kitao, S.- i.,
Kitayama, M.,
Shinohara, Y.,
Takasugi, M.,
Fujii, S.,
Kaminou, T.
Background and Purpose: Progressive changes in the substantia nigra pars compacta and locus ceruleus of patients with Parkinson disease and Alzheimer disease visualized by neuromelanin MRI and cardiac postganglionic sympathetic nerve function on (123)I-metaiodobenzylguanidine scintigraphy have not been fully evaluated. We compared the diagnostic value of these modalities among patients with early Parkinson disease, late […]
Phase II crossover trial of varenicline in mild-to-moderate Alzheimer’s disease
Kim, Seong Yoon,
Choi, Seong Hye,
Rollema, Hans,
Schwam, Elias M.,
McRae, Tom,
Dubrava, Sarah,
Jacobsen, Janice
Background: Evidence supports a role of α4β2 receptors in Alzheimer’s disease (AD).; Methods: This Korean, multicenter, double-blind, two-period (6 weeks each), crossover study randomized participants to the order in which they received varenicline (1 mg twice daily) and placebo. Assessments included AD Assessment Scale-Cognitive Subscale (ADAS-Cog) 75, Neuropsychiatric Inventory (NPI), adverse events (AEs) and Columbia-Suicide […]
Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ACE inhibitors
Hebert, Paul L.,
McBean, Alexander Marshall,
O'Connor, Heidi,
Frank, Barbara,
Good, Charles,
Maciejewski, Matthew L.
Background: Centrally active (CA) angiotensin-converting enzyme inhibitors (ACEIs) are able to cross the blood–brain barrier. Small observational studies and mouse models suggest that use of CA versus non-CA ACEIs is associated with a reduced incidence of Alzheimer’s disease and related dementias (ADRD).; Objective: The aim of this research was to assess the effect of CA […]
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors
Grossberg, George T.,
Manes, Facundo,
Allegri, Ricardo F.,
Gutiérrez-Robledo, Luis Miguel,
Gloger, Sergio,
Xie, Lei,
Jia, X. Daniel,
Pejović, Vojislav,
Miller, Michael L.,
Perhach, James L.,
Graham, Stephen M.
Introduction: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors.; Methods: In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of […]